Navigation Links
Watson to Acquire Arrow Group
Date:6/17/2009

s expertise in clinical, regulatory and legal matters. The combined management team has significant experience in executing international transactions as well as managing sales, marketing, production, R&D and regulatory functions on a global basis.
  • Financially Attractive Transaction: The transaction is anticipated to be accretive to cash earnings per share in 2010 before synergies, excluding the effect of transaction-related expenses and the amortization of intangible assets. It will be financed with a combination of cash and stock. Due to the modest amount of additional debt needed to complete this transaction, Watson will continue to have flexibility to be opportunistic in business development initiatives for both its generic and brand businesses.

  • Upon the close of the transaction, Tony Tabatznik, Founder and Chief Executive Officer of Arrow, is expected to join Watson's Board of Directors as a non-employee director.

    "Tony's vast industry experience, global commercial expertise and entrepreneurial spirit will be a valuable asset as Watson begins the next phase in its evolution," Mr. Bisaro continued. "The management team at Arrow is among the strongest in our industry, and we look forward to working with them to ensure a smooth integration, and longer term, to help maximize Watson's growth potential."

    Tony Tabatznik, Founder and Chief Executive Officer of Arrow, commented, "This is a brilliant move for both Watson and Arrow and we are very excited about being part of this great combination. Together we will have the resources, the skills and the capabilities to build one of the premier specialty pharmaceutical companies in the world."

    Transaction Terms

    Under the terms of the agreement, Watson will acquire Arrow for cash and stock consideration of $1.75 billion. The total consideration will include a cash p
    '/>"/>

    SOURCE Watson Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine news :

    1. Watson Files FDA Application for Generic Mucinex(R) D
    2. Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB)
    3. Watson-Marlow Releases Informative Video Featuring Showcased High Purity Pumps, Tubing and Fillers at Interphex 2009
    4. Watson Pharmaceuticals Reports First Quarter 2009 Results; Raises 2009 Outlook
    5. Watson Files FDA Applications for Generic Mucinex(R)
    6. Watson to Host and Webcast Investment Community Meeting at American Urological Association Annual Meeting
    7. Companies Continue To Add Wellness Programs, Watson Wyatt/National Business Group On Health Survey Finds
    8. Mark G. Watson Named Executive Director of Radiological Society of North America
    9. Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium
    10. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook
    11. Watson Acknowledges Federal Trade Commission Action Regarding AndroGel Patent Settlement
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/12/2014)... Lake City, Utah (PRWEB) July 12, 2014 ... spotlighted two types of startups, with awards being bestowed ... new emphasis spotlighted Utah’s outstanding entrepreneur community with recognition ... proving a sustainable model with incoming revenue. , 25 ... from across the state that are under 5 years ...
    (Date:7/12/2014)... article released by Seattle's well known plastic surgeon, Dr. Bryan ... cosmetic surgical procedures in summer months . , As ... enliven the rainy Pacific Northwest, many people are turning their ... out as much during the winter as they had planned. ... eager to look their best for their summer vacations, and ...
    (Date:7/12/2014)... (PRWEB) July 12, 2014 Wright & Schulte ... clients in Just For Men Lawsuits (case #59776/2014), announces ... consumers of reports that allege the popular hair dye, Just ... burns to their face, neck and other areas. In addition ... For Men chemical burns , the advertisements being run by ...
    (Date:7/12/2014)... July 12, 2014 Floor-grade ... of 4.1 out of 5. This above-average score ... been underpinning buyer negotiation power over the three ... Anna Son, “during the period, surging demand for ... associated with new product development, have placed upward ...
    (Date:7/12/2014)... 12, 2014 The largest pure occupational ... pleased to announce that it will be opening its ... facility will join four Atlanta-based Nova Medical Centers’ locations. ... 3209 Deans Bridge Road, and will be open from ... , “With Nova’s treatment philosophy of rapid return-to-work and ...
    Breaking Medicine News(10 mins):Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 2Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 3Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 4Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:Nova Medical Centers To Open New Facility in Augusta, Georgia 2
    ... intervention may be more effective, researchers say , , SUNDAY, ... rheumatoid arthritis could be identified and enrolled in clinical ... type of assessment and excluded two traditional assessments, according ... at 292 people, average age 54, seen at the ...
    ... at American Academy of Ophthalmology Annual Meeting Examines ... Glaucoma as Manifestation of a Larger Disease, NEW ORLEANS, ... the eye. For most of the 20th century, it was ... an,increasing number of non-pressure-dependent risk factors have been,identified, suggesting that ...
    ... Showed That Over a 6 Month Period, Nasacort AQ ... Significant Adrenal Suppression in This Same Age ... at,the American College of Allergy, Asthma & Immunology (ACAAI) ... Nasal Spray may be used safely and effectively to ...
    ... factor, study finds, urging greater outreach to bridge racial gap ... from transplant centers doesn,t explain why black Americans with end-stage ... placed on the kidney transplant waiting list, researchers say. ... end-stage renal (kidney) disease patients in Georgia and the Carolinas ...
    ... 9 Four members of the same,family, who ... Medicare Equipment,(DME) companies and Comprehensive Outpatient Rehabilitation Facilities ... for Medicare fraud, Assistant,Attorney General Alice S. Fisher ... Acosta of the Southern District of Florida announced ...
    ... Nov. 9 After several years of litigation,Merck has ... Vioxx. The,medication was pulled off the market in 2004 ... heart attacks and strokes. It is one of the,largest ... Smiljanich is pleased this long process is,coming to a ...
    Cached Medicine News:Health News:New Test Criteria Spots Rheumatoid Arthritis Sooner 2Health News:Looking at Glaucoma as a Systemic Disease 2Health News:Looking at Glaucoma as a Systemic Disease 3Health News:New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis 2Health News:New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis 3Health News:New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis 4Health News:New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis 5Health News:New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis 6Health News:Blacks in Poor Areas Less Likely to Be On Kidney Transplant Lists 2Health News:Four Miami Health Care Company Owners Sentenced to 57 Months in Prison For Medicare Fraud 2
    (Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
    (Date:7/10/2014)... Decision Resources Group finds that over half ... and Drug Administration,s (FDA) approval of Vifor Fresenius Medical ... approved by the FDA in November 2013 for the ... on dialysis. Other key findings from the ... : , Bundling: ...
    (Date:1/15/2014)... As health officials across the Midwest warn against the ... Michigan will offer free diagnostic testing ... pharmacists to administer tests and, in some cases, fill the ... in the study. The Grand Rapids, ...
    Breaking Medicine Technology:Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3
    ... 8 Lixte,Biotechnology Holdings, Inc. (OTC Bulletin Board: ... two different types of drugs being,developed as potential ... against human pancreatic cancers in a mouse model., ... of Lixte, said, "Lixte previously,reported that lead compounds ...
    ... Wash., Aug. 7 ProteoTech Inc. (ProteoTech),today announced ... requirements and has been cleared by the FDA ... Exebryl-1(R), a novel small molecule drug targeting,toxic beta-amyloid ... initiated its Phase 1 human trial on July ...
    Cached Medicine Technology:Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer 2ProteoTech's Exebryl-1(R) Enters Human Clinical Trials for the Treatment of Alzheimer's Disease 2
    A unique and cost effective one-piece adhesive closure patient bracelet with a tamper- resistant feature that has been designed for patient comfort, caregiver productivity, and long term durability....
    The IDENTI-PRINT II ID system functions as a complete, hospital wide patient identification system. It integrates the benefits of bedside labeling into a multipurpose ID band that consolidates admitt...
    ... The AeroScout Location Receiver is an ... Visibility System to outdoor and difficult ... and sophisticated location measurement capabilities packaged ... designed for harsh conditions. The Location ...
    ... facilitates real time information collection. It ... first module is a software link ... the database where information is captured ... the user interface, which allows access ...
    Medicine Products: